The multidisciplinary approach to thymoma: Combining molecular and clinical approaches

Journal of Thoracic Oncology

Volumn 5, Issue 10 SUPPL. 4, 2010, Pages

  Chau, Nicole G ^a   Kim, Edward S ^b   Wistuba, Ignacio ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b Division of Cancer Medicine   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

CDK TRKA inhibitors; Classification; DNA methyltransferase inhibitors; HDAC inhibitors; IGF 1R inhibitors; KIT inhibitors; Targeted therapy; Thymic carcinoma; Thymoma; VEGF inhibitors

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; BELINOSTAT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; DASATINIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; IFOSFAMIDE; IMATINIB; IMC A12; PACLITAXEL; PEMETREXED; PHA 848125AC; PREDNISONE; SORAFENIB; UNCLASSIFIED DRUG; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURGERY; DRUG MECHANISM; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THYMOMA; THYMUS CANCER; THYMUS CARCINOMA;

EID: 77957589737     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181f20d9a     Document Type: Article

References (48)

1. Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 2003;105:546-551.
2. Travis WB, Brambilla E, Muller-Hermelinck HK, et al., editors. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004.
3. Suster S, Moran CA. Thymoma classification: current status and future trends. Am J Clin Pathol 2006;125:542-554.
4. Kuhn E, Wistuba II. Molecular pathology of thymic epithelial neoplasms. Hematol Oncol Clin North Am 2008;22:443-455.
5. Inoue M, Starostik P, Zettl A, et al. Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res 2003;63:3708-3715.
6. Girard N, Shen R, Guo T, et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009;15:6790-6799.
7. Zettl A, Strobel P, Wagner K, et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 2000;157:257-266.
8. Sasaki H, Ide N, Fukai I, et al. Gene expression analysis of human thymoma correlates with tumor stage. Int J Cancer 2002;101:342-347.
9. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 2003;76:878-884; discussion 84-85.
10. Berruti A, Borasio P, Gerbino A, et al. Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. Br J Cancer 1999; 81:841-845.
11. Kim ES, Putnam JB, Komaki R, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 2004;44:369-379.
12. Loehrer PJ Sr, Chen M, Kim K, et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage un-resectable thymoma: an intergroup trial. J Clin Oncol 1997;15:3093-3099.
13. Giaccone G, Ardizzoni A, Kirkpatrick A, et al. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1996;14:814-820.
14. Loehrer PJ Sr, Jiroutek M, Aisner S, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 2001;91: 2010-2015.
15. Lemma GL, Loehrer PJ Sr, Lee JW, et al. A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99. J Clin Oncol 2008;20(suppl):8018.
16. Loehrer PJ, Yiannoutsos CT, Dropcho S, et al. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. In: 2006 ASCO Annual Meeting; 2006:2006.
17. Liu JM, Wang LS, Huang MH, et al. Topoisomerase 2alpha plays a pivotal role in the tumor biology of stage IV thymic neoplasia. Cancer 2007;109:502-509.
18. Sasaki H, Fukai I, Kiriyama M, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in thymoma. Surg Today 2003;33:83-8.
19. Ionescu DN, Sasatomi E, Cieply K, et al. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 2005;103:630-636.
20. Suzuki E, Sasaki H, Kawano O, et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 2006;36:351-356.
21. Henley JD, Cummings OW, Loehrer PJ Sr. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 2004;130:222-224.
22. Meister M, Schirmacher P, Dienemann H, et al. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. Cancer Lett 2007;248:186-191.
23. Kurup A, Burns M, Dropcho S, et al. Phase II study of gefitinib treatment in advanced thymic malignancies. J Clin Oncol 2005;23:7068.
24. Christodoulou C, Murray S, Dahabreh J, et al. Response of malignant thymoma to erlotinib. Ann Oncol 2008;19:1361-1362.
25. Yoh K, Nishiwaki Y, Ishii G, et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 2008;62:316-320.
26. Yamaguchi H, Soda H, Kitazaki T, et al. Thymic carcinoma with epidermal growth factor receptor gene mutations. Lung Cancer 2006; 52:261-262.
27. Farina G, Garassino MC, Gambacorta M, et al. Response of thymoma to cetuximab. Lancet Oncol 2007;8:449-450.
28. Palmieri G, Marino M, Salvatore M, et al. Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci 2007;12:757-761.
29. Pan CC, Chen PC, Wang LS, et al. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopathology 2003;43:165-172.
30. Suzuki M, Chen H, Shigematsu H, et al. Aberrant methylation: common in thymic carcinomas, rare in thymomas. Oncol Rep 2005;14:1621-1624.
31. Nakagawa K, Matsuno Y, Kunitoh H, et al. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest 2005;128:140-144.
32. Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 2004;202: 375-381.
33. Strobel P, Hartmann M, Jakob A, et al. Thymic carcinoma with over-expression of mutated KIT and the response to imatinib. N Engl J Med 2004;350:2625-2626.
34. Tsuchida M, Umezu H, Hashimoto T, et al. Absence of gene mutations in KIT-positive thymic epithelial tumors. Lung Cancer 2008;62:321-325.
35. Chuah C, Lim TH, Lim AS, et al. Dasatinib induces a response in malignant thymoma. J Clin Oncol 2006;24:e56-e58.
36. Giaccone G, Smit EF, van Groeningen C, et al. Phase II study of imatinib in patients with WHO B3 and C thymomas. J Clin Oncol 2008;26:14665.
37. Bisagni G, Rossi G, Cavazza A, et al. Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 2009;4:773-775.
38. Salter JT, Lewis D, Yiannoutsos C, et al. Imatinib for the treatment of thymic carcinoma. J Clin Oncol 2008;26:8116.
39. Li XF, Chen Q, Huang WX, et al. Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Med Oncol 2009;26:157-160.
40. Steele NL, Plumb JA, Vidal L, et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008;14:804 - 810.
41. Giaccone G, Rajan A, Carter C, et al. Phase II study of the histone deacetylase inhibitor belinostat in thymic malignancies. J Clin Oncol 2009;27(suppl):abstr 7589.
42. Brunetto AT, Ang JE, Lai R, et al. A first-in-human phase I study of 4SC-201, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors. J Clin Oncol 2009;27:15s:3530.
43. Cimpean AM, Raica M, Encica S, et al. Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann Anat 2008;190:238-245.
44. Bedano PM, Perkins S, Burns M, et al. A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 2008;26(suppl):19087.
45. Isambert N, Freyer G, Zanetta S, et al. A phase I dose escalation and pharmacokinetic study of intravenous aflibercept (VEGF trap) plus docetaxel in patients with advanced solid tumors: Preliminary results. J Clin Oncol 2008;28(suppl):3599.
46. Azad A, Herbertson RA, Pook D, et al. Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma. Acta Oncol 2009;48:619-621.
47. Stewart DJ, Issa JP, Kurzrock R, et al. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 2009;15:3881-3888.
48. Kim ES, Herbst RS, Lee JL, et al. The BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination): personalizing therapy for lung cancer. In: 2010 AACR Annual Meeting, Washington Convention Center, 2010. Abstr no. LB1.